Sam Aparicio (Principal Medical Consultant), graduated in Medical and Natural Sciences from Cambridge University and was trained clinically in internal medicine in Oxford and London and Pathology in Cambridge. He currently holds the Nan and Lorraine Robertson Chair based at UBC/BC Cancer Agency, Vancouver Canada and a Canada Research Chair in molecular oncology. He is a co-founder of Paradigm and was Director of Science between 1999 and 2004.

Dr. Samuel Aparicio is recognized widely for his contributions to genomics and translational medicine.

Most recently in the position of senior principal investigator at the Hutchinson-MRC Research Centre at Cambridge University, and Chief Scientific Officer of Paradigm Therapeutics, Dr. Aparicio's work spans the sequencing and analysis of the puffer fish genome, the identification of gene regulatory sequences, and the discovery of new human drug targets through mouse genetic models.

The focus of Dr. Aparicio's research program is using genetics and genomics to better understand the development of breast cancer, help devise improved detection methods, and identify new therapies. His work will contribute to a basic understanding of other cancers, and he expects to work closely with the ovarian and prostate cancer groups in Vancouver.